针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BA.2.12.1、BA.4和BA.5亚变体的加强mRNA疫苗的持久性 - Suppr

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.

作者信息

Qu Panke, Faraone Julia N, Evans John P, Zheng Yi-Min, Yu Lianbo, Ma Qin, Carlin Claire, Lozanski Gerard, Saif Linda J, Oltz Eugene M, Gumina Richard J, Liu Shan-Lu

机构信息

Ohio State University, Columbus, Ohio

出版信息

N Engl J Med. 2022 Oct 6;387(14):1329-1331. doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7.

DOI:10.1056/NEJMc2210546

PMID:36069925

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9511629/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a851/9511629/d91dee9eb2c0/NEJMc2210546_f1.jpg

相似文献

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BA.2.12.1、BA.4和BA.5亚变体的加强mRNA疫苗的持久性

N Engl J Med. 2022 Oct 6;387(14):1329-1331. doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7.

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.mRNA 疫苗与 BBV152 疫苗加强针对奥密克戎亚变种的免疫原性：PRIBIVAC 研究 B 阶段的最终结果，一项随机临床试验。

Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5.

COVID-19 mRNA Vaccine Booster During Pregnancy Increases Maternal and Fetal Antibodies.孕期接种新冠病毒mRNA加强针可增加母体和胎儿抗体。

JAMA. 2022 Jul 12;328(2):120-121. doi: 10.1001/jama.2022.11145.

Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.二价（Asp614Gly和奥密克戎BA.4/5变体）自我扩增mRNA SARS-CoV-2加强疫苗与BNT162b2奥密克戎BA.4/5 mRNA疫苗加强剂量的免疫原性：一项随机3期试验。

Lancet Infect Dis. 2025 Mar;25(3):290-300. doi: 10.1016/S1473-3099(24)00565-6. Epub 2024 Oct 23.

Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.测定接受单价原始株灭活全病毒或 mRNA 疫苗或双价 WT/BA.4-5 COVID-19 mRNA 疫苗作为加强针的成年人对 XBB 变异株的 T 细胞反应。

Int J Infect Dis. 2024 Dec;149:107271. doi: 10.1016/j.ijid.2024.107271. Epub 2024 Oct 18.

Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.针对 COVID-19 的一种改良信使核糖核酸-脂质纳米颗粒候选疫苗的安全性和免疫原性：一项 1 期、剂量递增研究的结果。

Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18.

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.安全性、免疫原性和异源加强用 SARS-CoV-2 mRNA 疫苗（SYS6006）在中国 18 岁及以上人群中的效果：一项随机、开放标签、阳性对照的 3 期临床试验。

Emerg Microbes Infect. 2024 Dec;13(1):2320913. doi: 10.1080/22221751.2024.2320913. Epub 2024 Feb 29.

S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.德尔塔和奥密克戎变异株刺突蛋白中的S6P突变显著提高了新冠mRNA疫苗的效力。

Front Immunol. 2025 Jan 3;15:1495561. doi: 10.3389/fimmu.2024.1495561. eCollection 2024.

Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.对≥60 岁人群接种二价（原始/Omicron BA.4-5）mRNA 疫苗加强针对严重 COVID-19 的有效性：意大利，2022-2023 年，根据不同 Omicron 亚变体流行期间的日历时间和接种后时间估算

Vaccine. 2024 Oct 3;42(23):126026. doi: 10.1016/j.vaccine.2024.05.074. Epub 2024 Jun 3.

A Bivalent Omicron-Containing Booster Vaccine against Covid-19.二价含奥密克戎成分的新冠病毒加强疫苗。

N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.

引用本文的文献

COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.COVID-19信使核糖核酸疫苗联合淋巴泵整骨手法治疗的免疫反应：一项随机对照试验

Virus Res. 2025 Jul 14;359:199607. doi: 10.1016/j.virusres.2025.199607.

Boosting mRNA cancer vaccine efficacy via targeting on macrophages in lymph nodes.通过靶向淋巴结中的巨噬细胞提高mRNA癌症疫苗疗效。

Theranostics. 2025 May 25;15(13):6329-6346. doi: 10.7150/thno.110305. eCollection 2025.

SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023.2020年至2023年挪威队列中的新冠病毒特异性体液免疫

BMC Med. 2025 Jun 3;23(1):332. doi: 10.1186/s12916-025-04171-2.

Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates.基于mRNA的新型冠状病毒变异株疫苗在非人灵长类动物中的保护效力

Acta Pharm Sin B. 2025 Feb;15(2):934-946. doi: 10.1016/j.apsb.2024.12.003. Epub 2024 Dec 7.

Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers.儿科医护人员中新冠病毒抗体的纵向监测

Vaccines (Basel). 2025 Feb 7;13(2):163. doi: 10.3390/vaccines13020163.

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers.新冠疫苗加强针未能增强再次感染的医护人员对奥密克戎变异株的抗体反应。

Viruses. 2025 Jan 9;17(1):78. doi: 10.3390/v17010078.

Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort.恢复期队列中针对新出现的SARS-CoV-2变体的疫苗增强体液免疫反应的特征分析

Pathogens. 2025 Jan 8;14(1):44. doi: 10.3390/pathogens14010044.

Tissue-resident memory T cells contribute to protection against heterologous SARS-CoV-2 challenge.组织驻留记忆T细胞有助于抵御异源严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的攻击。

JCI Insight. 2024 Dec 6;9(23):e184074. doi: 10.1172/jci.insight.184074.

More severe comorbidities, advanced age, and incomplete vaccination increase the risk of COVID-19 mortality.更严重的合并症、高龄和未完成疫苗接种会增加新冠病毒感染相关死亡风险。

Narra J. 2024 Aug;4(2):e949. doi: 10.52225/narra.v4i2.949. Epub 2024 Aug 14.

Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023.2022 年 9 月至 2023 年 8 月，芬兰≥65 岁人群中，二价加强针针对 COVID-19 重症结局的相对有效性。

Euro Surveill. 2024 Sep;29(37). doi: 10.2807/1560-7917.ES.2024.29.37.2300587.

本文引用的文献

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.新型冠状病毒奥密克戎BA.4/5和BA.2.12.1亚变体的中和作用

N Engl J Med. 2022 Jun 30;386(26):2526-2528. doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15.

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.mRNA 疫苗预防卡塔尔奥密克戎 BA.1 和 BA.2 亚变种对 SARS-CoV-2 的保护持续时间。

Nat Commun. 2022 Jun 2;13(1):3082. doi: 10.1038/s41467-022-30895-3.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.SARS-CoV-2 mRNA 疫苗接种引起的中和抗体反应随时间推移而减弱，并因突破性感染而增强。

Sci Transl Med. 2022 Mar 23;14(637):eabn8057. doi: 10.1126/scitranslmed.abn8057.

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.卡塔尔既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与mRNA疫苗接种后突破性感染风险的关联

JAMA. 2021 Nov 16;326(19):1930-1939. doi: 10.1001/jama.2021.19623.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献